Xaliproden: Phase III data

In the double-blind, international Phase III XENOX trial in 648 patients, Xaliproden plus FOLFOX4 met the primary endpoint of occurrence of PSN compared to placebo plus FOLFOX4. FOLFOX4 chemotherapy r...